Regulatory News has published 1 story about Armata Pharmaceuticals on 15 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 15 September 2026.
This page is generated from Regulatory News’ editorial coverage of Armata Pharmaceuticals. It is not an advertisement.
On the record
- Company
- Armata Pharmaceuticals, Inc. (NYSE American: ARMP)
- Headquarters
- Los Angeles, California
- Founded
- 2019, by the merger of C3J Therapeutics and AmpliPhi Biosciences
- Regulator
- U.S. Food and Drug Administration (CDER)
- Latest milestone
- FDA Breakthrough Therapy designation, AP-SA02
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
